DocGo Förvaltning
Förvaltning kriterier kontrolleras 2/4
DocGo VD är Lee Bienstock, utsedd i Sep 2023, har en mandatperiod på 2.75 år. totala årliga ersättningen är $ 3.57M, bestående av 22% lön 78% bonusar, inklusive företagsaktier och optioner. äger direkt 0.69% av företagets aktier, värda $ 387.67K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 3.5 år respektive 2.2 år.
Viktig information
Lee Bienstock
Verkställande direktör
US$3.6m
Total ersättning
| VD-lön i procent | 21.98% |
| Anställning som VD | 2.8yrs |
| Ägande av VD | 0.7% |
| Ledningens genomsnittliga anställningstid | 3.5yrs |
| Styrelsens genomsnittliga mandatperiod | 2.2yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • Jun 17
DCGO: Future Returns Will Rely On Raised 2026 Revenue Guidance
Analysts have trimmed their price target on DocGo stock by $0.50, citing updated assumptions around revenue growth, profit margins, and future P/E expectations reflected in recent research commentary. What’s in the News for DocGo DocGo raised its full year 2026 revenue guidance to a range of $300 million to $315 million, compared with prior guidance of $290 million to $310 million and initial guidance of $280 million to $300 million.
Uppdatering av berättelse • Jun 03
DCGO: Transport EBITDA Outlook And 2026 Guidance Will Support Future Upside
Analysts have trimmed their price targets on DocGo to around $2.50, reflecting mixed Q4 results, a modestly updated growth outlook in the transport segment, and the view that transportation EBITDA potential of $15m to $20m in 2026 could still imply value above the current share price, even with a lower projected P/E and slightly higher risk assumptions. Analyst Commentary Bullish analysts are trimming price targets yet still flagging areas where they see room for upside if execution improves, especially in DocGo's transportation segment.Analysartikel • May 14
US$1.87: That's What Analysts Think DocGo Inc. (NASDAQ:DCGO) Is Worth After Its Latest Results
DocGo Inc. ( NASDAQ:DCGO ) shareholders are probably feeling a little disappointed, since its shares fell 5.5% to...
Uppdatering av berättelse • May 14
DCGO: Transport EBITDA And 2026 Guidance Will Support Future Upside Potential
Narrative Update The consensus analyst price target for DocGo has been reduced toward the mid single digit range, with cuts such as the move from $4.00 to $2.50. Analysts are factoring in mixed Q4 results, modestly higher 2026 transport guidance, updated fair value estimates near $1.87, a slightly higher discount rate of about 7.3%, revised revenue growth assumptions around 4.2%, a profit margin assumption near 6.1%, and a lower future P/E closer to 10.8x.Uppdatering av berättelse • Apr 23
DCGO: Transport EBITDA Outlook Will Drive Future Upside Potential
Analysts recently trimmed their DocGo price targets, with cuts such as Stifel's move from $4.00 to $2.50, citing mixed Q4 results, modestly higher 2026 transport guidance, and updated expectations for growth, margins, and P/E assumptions. Analyst Commentary Bullish analysts acknowledge the recent price target cuts but still point to several areas they see as supportive for DocGo's valuation and long term execution story.Uppdatering av berättelse • Apr 07
DCGO: Transport EBITDA And 2026 Guidance Will Drive Future Upside Potential
Narrative Update Analysts have nudged their price expectations for DocGo lower, trimming aggregate targets by around $0.10 as they factor in mixed Q4 results, modestly higher 2026 transport guidance, and updated views on margins, growth, and future P/E multiples. Analyst Commentary Recent Street commentary on DocGo is mixed, with some analysts focusing on potential value in the transport segment and others reacting to lower price targets and Q4 variability.Uppdatering av berättelse • Mar 24
DCGO: Transport EBITDA Outlook Will Support Future Upside Potential
Narrative Update The analyst price target for DocGo has been reduced from $4.00 to $2.50, as analysts factor in mixed Q4 results while crediting modestly higher 2026 transport guidance and the view that the transport unit alone could potentially support proceeds above the current share price. Analyst Commentary Recent research reflects a more cautious stance on DocGo, with the price target reduced to US$2.50 while still crediting specific strengths in the transport segment.Uppdatering av berättelse • Mar 10
DCGO: Future Returns Will Rely On Expanding Telehealth Weight Loss Services
Analysts have trimmed their price targets on DocGo to reflect slightly softer revenue growth assumptions, along with somewhat stronger profit margin and future P/E expectations, resulting in only a modest adjustment to their overall valuation view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the $1.00 minimum bid price requirement.Uppdatering av berättelse • Feb 22
DCGO: Buyback Extension And Telehealth Expansion Will Support Future Upside
Analysts have trimmed their price targets on DocGo to $2.50, citing slightly higher discount rate assumptions, a modestly softer profit margin outlook, and a higher future P/E multiple as key drivers of the revised view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the minimum US$1.00 bid price requirement, triggering a 180 day window until July 27, 2026 to regain compliance before potential further action is considered (Delistings).Uppdatering av berättelse • Feb 08
DCGO: Future Returns Will Rely On Expanding Longitudinal Virtual Weight Loss Care
Analysts have slightly reduced their price target on DocGo, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. This adjustment signals a more cautious stance on the company’s risk and earnings profile.Uppdatering av berättelse • Jan 24
DCGO: Buyback Extension And M&A Pipeline Will Support Future Upside
Analysts have trimmed their price target on DocGo to reflect a fair value shift from about $3.08 to roughly $2.50. The change reflects updated assumptions around revenue contraction, slightly higher required returns, modestly better profit margins, and a lower future P/E multiple.Uppdatering av berättelse • Jan 10
DCGO: Future Returns Will Depend On Expanding Longitudinal Care Partnerships
Analysts have made a small upward tweak to their price target on DocGo, reflecting slightly more constructive assumptions around revenue growth and long term profit margins, while keeping the projected P/E and discount rate almost unchanged. What's in the News Robbins Geller Rudman & Dowd LLP announced a proposed US$12.5 million cash settlement in the DocGo securities class action, subject to court approval at a hearing scheduled for March 24, 2026 in the Southern District of New York (Lawsuits & Legal Issues).Uppdatering av berättelse • Dec 26
DCGO: Future Returns Will Depend On Longitudinal Care And Maturing Revenue Mix
Analysts have nudged up their price target on DocGo by a modest amount, citing slightly higher long term profit margin expectations and a marginally richer future earnings multiple. Together, these factors support a small increase in estimated fair value.Uppdatering av berättelse • Dec 12
DCGO: Future Returns Will Depend On New Longitudinal Care Contracts
Analysts have lowered their price target on DocGo from approximately 1.60 dollars to 1.00 dollars, citing a higher required discount rate and a reduced valuation multiple, despite modest improvements in the projected revenue trajectory and profit margins. What's in the News DocGo signaled an active mergers and acquisitions strategy, highlighting its ability to acquire traditional health care assets and layer on its technology and mobile health capabilities to support long-term growth and shareholder value (company commentary) The company provided updated guidance, forecasting 2025 revenue of 315 million to 320 million dollars, including 68 million to 70 million dollars from migrant-related contracts, and 2026 revenue of 280 million to 300 million dollars with no migrant-related revenue (corporate guidance) DocGo recorded a goodwill impairment charge of approximately 8.7 million dollars in the third quarter of 2025, reflecting a write-down of acquired assets (company filing) DocGo announced a new Longitudinal Care Services program with a California-based insurer, targeting 10,000 under-engaged members with combined telehealth and in-home clinical services starting in the fourth quarter (client announcement) The company is expanding its partnership with a national insurer in New Mexico, launching care gap closure and planned primary care services for 10,000 Turquoise Care members through at-home visits and chronic care support (client announcement) Valuation Changes The fair value estimate has fallen significantly from approximately $1.60 to $1.00 per share.Analysartikel • Sep 26
Benign Growth For DocGo Inc. (NASDAQ:DCGO) Underpins Its Share Price
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Analysartikel • May 16
DocGo Inc. (NASDAQ:DCGO) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the DocGo Inc. ( NASDAQ:DCGO ) share price has dived 38% in the last thirty days...Analysartikel • Apr 16
Is It Too Late To Consider Buying DocGo Inc. (NASDAQ:DCGO)?
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it saw significant share price movement during recent...Analysartikel • Mar 06
We Like The Quality Of DocGo's (NASDAQ:DCGO) Earnings
Despite posting healthy earnings, DocGo Inc.'s ( NASDAQ:DCGO ) stock has been quite weak. We have done some analysis...Analysartikel • Mar 01
These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Feb 11
Subdued Growth No Barrier To DocGo Inc. (NASDAQ:DCGO) With Shares Advancing 33%
DocGo Inc. ( NASDAQ:DCGO ) shareholders have had their patience rewarded with a 33% share price jump in the last month...
Ny berättelse • Sep 24
Innovative Health Initiatives Promise Growth Amid Analysts' Concerns Over Future Earnings And Margins
Strategic partnerships with virtual-only providers and operational efficiency improvements indicate a comprehensive approach to expanding health solutions and improving margins.Analysartikel • Aug 05
DocGo Inc. (NASDAQ:DCGO) Doing What It Can To Lift Shares
DocGo Inc.'s ( NASDAQ:DCGO ) price-to-earnings (or "P/E") ratio of 15.3x might make it look like a buy right now...Analysartikel • Jul 17
At US$3.40, Is DocGo Inc. (NASDAQ:DCGO) Worth Looking At Closely?
DocGo Inc. ( NASDAQ:DCGO ), might not be a large cap stock, but it saw a decent share price growth of 20% on the...Analysartikel • Jun 11
These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Seeking Alpha • Mar 20
DocGo: Upside Remains Attractive After Share Price Decline
Summary DocGo stock receives a buy rating due to attractive upside potential and commendable execution demonstrated by management. Recent results show strong revenue growth and margin expansion, driven by steady contracts and growth in trip volumes and average price. Management's positive commentary, impressive pipeline, and plans for RFP submissions in FY24 indicate continued momentum and cross-sell success. Read the full article on Seeking AlphaAnalysartikel • Feb 13
Does DocGo (NASDAQ:DCGO) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 05
DocGo: Good Performance, Trust Issues
Summary DocGo has recently faced a series of negative events, including criticism from the NY Times, Comptroller contract rejection, CEO departure on false CV allegations, and a short report. Despite these challenges, the company presented strong Q3 2023 results, positively revised FY 2023 guidance, addressed the short report, announced new partnerships and a share repurchase program. Investors must decide if they should trust DocGo's performance and financials or let the dust settle first. Read the full article on Seeking AlphaAnalys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$188m |
| Dec 31 2025 | US$4m | US$785k | -US$182m |
| Sep 30 2025 | n/a | n/a | -US$52m |
| Jun 30 2025 | n/a | n/a | -US$18m |
| Mar 31 2025 | n/a | n/a | -US$641k |
| Dec 31 2024 | US$8m | US$785k | US$20m |
| Sep 30 2024 | n/a | n/a | US$31m |
| Jun 30 2024 | n/a | n/a | US$30m |
| Mar 31 2024 | n/a | n/a | US$22m |
| Dec 31 2023 | US$11m | US$582k | US$7m |
| Sep 30 2023 | n/a | n/a | US$7m |
| Jun 30 2023 | n/a | n/a | US$6m |
| Mar 31 2023 | n/a | n/a | US$20m |
| Dec 31 2022 | US$4m | US$415k | US$35m |
Ersättning vs marknad: Lee s total kompensation ($USD 3.57M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 647.34K ).
Ersättning vs inkomst: Ersättningen från Lee har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Lee Bienstock (41 yo)
2.8yrs
Anställning
US$3,571,951
Kompensation
Mr. Lee Bienstock served as President at DocGo Inc. since December 31, 2022 until September 15, 2023. He served as Chief Operating Officer at DocGo Inc. since March 2022 until September 15, 2023 and serves...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$3.57m | 0.69% $ 387.7k | |
| Treasurer & CFO | 3.5yrs | US$1.70m | 0.35% $ 194.1k | |
| General Counsel | 4.6yrs | US$1.32m | 0.094% $ 52.3k | |
| Chief Information Officer | 1.8yrs | inga uppgifter | inga uppgifter | |
| Vice President of Investor Relations | no data | inga uppgifter | inga uppgifter | |
| Chief Compliance Officer | 4.3yrs | US$1.84m | 0.15% $ 83.7k | |
| Vice President of Human Resources | no data | inga uppgifter | inga uppgifter | |
| CEO of Clinical Practice Group & Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter |
3.5yrs
Genomsnittlig anställningstid
54.5yo
Genomsnittlig ålder
Erfaren ledning: DCGO s ledningsgrupp anses vara erfaren ( 3.5 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 2.2yrs | US$3.57m | 0.69% $ 387.7k | |
| General Counsel | 4.6yrs | US$1.32m | 0.094% $ 52.3k | |
| CEO of Clinical Practice Group & Member of Medical Advisory Board | 2yrs | inga uppgifter | inga uppgifter | |
| Independent Chair | 4.6yrs | US$225.50k | 0.61% $ 343.5k | |
| Independent Director | 4.6yrs | US$193.00k | 0.45% $ 253.1k | |
| Member of Medical Advisory Board | 2yrs | inga uppgifter | inga uppgifter | |
| Member of Medical Advisory Board | 2yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 3.6yrs | US$208.00k | 0.017% $ 9.3k | |
| Independent Director | 4.6yrs | US$234.25k | 0.057% $ 31.7k | |
| Chairman of Medical Advisory Board | 2yrs | inga uppgifter | inga uppgifter | |
| Member of Medical Advisory Board | 2yrs | inga uppgifter | inga uppgifter |
2.2yrs
Genomsnittlig anställningstid
62.5yo
Genomsnittlig ålder
Erfaren styrelse: DCGO s styrelse anses inte vara erfaren ( 2.2 års genomsnittlig mandatperiod), vilket föreslår en ny styrelse.
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/18 00:40 |
| Aktiekurs vid dagens slut | 2026/06/18 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
DocGo Inc. bevakas av 7 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Sarah James | Barclays |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |